Tuberous Sclerosis Complex (TSC) - Market Insights, Epidemiology and Market Forecast-2027
This report can be delivered to the clients within 24 Hours
DelveInsight’s ‘Tuberous Sclerosis Complex (TSC) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of TSC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Tuberous Sclerosis Complex (TSC) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
Tuberous Sclerosis Complex (TSC) - Disease Understanding and Treatment Algorithm
The DelveInsight Tuberous Sclerosis Complex (TSC) market report gives the thorough understanding of the Tuberous Sclerosis Complex (TSC) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Tuberous Sclerosis Complex (TSC) in the US, Europe, and Japan.
Tuberous Sclerosis Complex (TSC) Epidemiology
The Tuberous Sclerosis Complex (TSC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, De novo mutations cases and Familiar Cases) scenario of Tuberous Sclerosis Complex (TSC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total prevalent population of Tuberous Sclerosis Complex (TSC) was found to be 101,399, in the year 2016.
Tuberous Sclerosis Complex (TSC) Drug Chapters
This segment of the Tuberous Sclerosis Complex (TSC) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, mTOR inhibitors are frequently used as an effective medication to treat various manifestations of tuberous sclerosis. Afinitor/Votubia is the only approved mTOR inhibitor for Subependymal Giant Cell Astrocytomas, Seizures and Angiomyolipomas treatment of patients who are not eligible for surgery. Detailed chapter of upcoming therapies such as Epidiolex (GW Pharmaceuticals) and TAK-935 (Takeda Pharmaceutical Company Limited) have also been covered in the report.
Tuberous Sclerosis Complex (TSC) Market Outlook
The Tuberous Sclerosis Complex (TSC) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Tuberous Sclerosis Complex (TSC) in 7MM was found to be USD 372 million in 2016.
Tuberous Sclerosis Complex (TSC) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Tuberous Sclerosis Complex (TSC) Report Insights
DelveInsight’s ‘Tuberous Sclerosis Complex (TSC) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of TSC in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Tuberous Sclerosis Complex (TSC) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Tuberous Sclerosis Complex (TSC) - Disease Understanding and Treatment Algorithm
The DelveInsight Tuberous Sclerosis Complex (TSC) market report gives the thorough understanding of the Tuberous Sclerosis Complex (TSC) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Tuberous Sclerosis Complex (TSC) in the US, Europe, and Japan.
Tuberous Sclerosis Complex (TSC) Epidemiology
The Tuberous Sclerosis Complex (TSC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent cases, De novo mutations cases and Familiar Cases) scenario of Tuberous Sclerosis Complex (TSC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, the total prevalent population of Tuberous Sclerosis Complex (TSC) was found to be 101,399, in the year 2016.
Tuberous Sclerosis Complex (TSC) Drug Chapters
This segment of the Tuberous Sclerosis Complex (TSC) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
At present, mTOR inhibitors are frequently used as an effective medication to treat various manifestations of tuberous sclerosis. Afinitor/Votubia is the only approved mTOR inhibitor for Subependymal Giant Cell Astrocytomas, Seizures and Angiomyolipomas treatment of patients who are not eligible for surgery. Detailed chapter of upcoming therapies such as Epidiolex (GW Pharmaceuticals) and TAK-935 (Takeda Pharmaceutical Company Limited) have also been covered in the report.
Tuberous Sclerosis Complex (TSC) Market Outlook
The Tuberous Sclerosis Complex (TSC) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Tuberous Sclerosis Complex (TSC) in 7MM was found to be USD 372 million in 2016.
Tuberous Sclerosis Complex (TSC) Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Tuberous Sclerosis Complex (TSC) Report Insights
- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices
- Unmet Needs
- Detailed Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Tuberous Sclerosis Complex (TSC) market
- Organize sales and marketing efforts by identifying the best opportunities for Tuberous Sclerosis Complex (TSC) market
- To understand the future market competition in the Tuberous Sclerosis Complex (TSC) market.
1. KEY INSIGHTS
2. TUBEROUS SCLEROSIS COMPLEX (TSC) MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of TSC in 2017
2.2. Market Share (%) Distribution of TSC in 2027
3. DISEASE OVERVIEW: TUBEROUS SCLEROSIS COMPLEX (TSC)
3.1. Introduction
3.2. Clinical Manifestations of Tuberous Sclerosis Complex
3.3. Etiology
3.4. Risk Factors
3.5. Inheritance Pattern
3.6. Signs and Symptoms
3.7. Pathophysiology
3.7.1. Tuberous Sclerosis Complex (TSC) Genotype Analysis
3.8. Diagnosis
3.8.1. Differential Diagnosis
3.8.2. Diagnostic Criteria
3.8.3. Diagnostic Recommendations
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
5. 7MM TOTAL PREVALENT PATIENT POPULATION OF TUBEROUS SCLEROSIS COMPLEX
6. COUNTRY WISE-EPIDEMIOLOGY OF TUBEROUS SCLEROSIS COMPLEX
6.1. United States
6.1.1. Prevalent Population of Tuberous Sclerosis Complex in the United States
6.1.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.1.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.2. Germany
6.2.1. Prevalent Population of Tuberous Sclerosis Complex in Germany
6.2.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.2.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.3. France
6.3.1. Prevalent Population of Tuberous Sclerosis Complex in France
6.3.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.3.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.4. Italy
6.4.1. Prevalent Population of Tuberous Sclerosis Complex in Italy
6.4.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.4.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.5. Spain
6.5.1. Prevalent Population of Tuberous Sclerosis Complex in Spain
6.5.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.5.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.6. United Kingdom
6.6.1. Prevalent Population of Tuberous Sclerosis Complex in the UK
6.6.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.6.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.7. Japan
6.7.1. Prevalent Population of Tuberous Sclerosis Complex in Japan
6.7.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.7.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
7. CURRENT TREATMENT PRACTICES
7.1. Therapeutic Goals
7.2. General Treatment Practices
7.3. Treatment Algorithm
7.4. Treatment Guidelines
7.4.1. International Tuberous Sclerosis Complex Consensus Conference: Tuberous Sclerosis Complex Surveillance and Management: Recommendations
8. UNMET NEEDS
9. MARKETED DRUGS
9.1. Comparison of Marketed Drugs
9.2. Everolimus: Novartis Pharmaceuticals
9.2.1. Product Description
9.2.2. Mechanism of Action
9.2.3. Regulatory Milestones
9.2.4. Safety and Efficacy
9.2.5. Side effects
9.2.6. Product Profile
9.3. Rapalimus: Nobelpharma Co., Ltd
9.3.1. Product Description
9.3.2. Mechanism of Action
9.3.3. Regulatory Milestones
9.3.4. Safety and Efficacy
9.3.5. Side effects
9.3.6. Product Profile
10. EMERGING THERAPIES
10.1. Emerging Therapies: Key Cross Comparison
10.2. Epidiolex: GW Pharmaceuticals
10.2.1. Drug Description
10.2.2. Regulatory Milestones
10.2.3. Other Development Activities
10.2.4. Clinical Development
10.2.5. Clinical Trials Information
10.2.6. Product Profile
10.3. TAK-935: Takeda Pharmaceutical Company Limited
10.3.1. Drug Description
10.3.2. Other Development Activities
10.3.3. Clinical Development
10.3.4. Clinical Trials Information
10.3.5. Product Profile
11. TUBEROUS SCLEROSIS COMPLEX: 7 MAJOR MARKET ANALYSIS
11.1. Key Findings
11.2. Market Size of Tuberous Sclerosis Complex in 7MM
12. MARKET OUTLOOK BY COUNTRY
13. THE UNITED STATES: MARKET OUTLOOK
13.1. United States Market Size
13.1.1. Total Market size of Tuberous Sclerosis Complex
13.1.2. Tuberous Sclerosis Complex Market by Therapies
14. EU-5 COUNTRIES: MARKET OUTLOOK
14.1. Germany
14.1.1. Total Market size of Tuberous Sclerosis Complex
14.1.2. Tuberous Sclerosis Complex Market by Therapies
14.2. France
14.2.1. Total Market size of Tuberous Sclerosis Complex
14.2.2. Tuberous Sclerosis Complex Market by Therapies
14.3. United Kingdom
14.3.1. Total Market size of Tuberous Sclerosis Complex
14.3.2. Tuberous Sclerosis Complex Market by Therapies
14.4. Spain
14.4.1. Total Market size of Tuberous Sclerosis Complex
14.4.2. Tuberous Sclerosis Complex Market by Therapies
14.5. Italy
14.5.1. Total Market size of Tuberous Sclerosis Complex
14.5.2. Tuberous Sclerosis Complex Market by Therapies
14.6. Japan: Market Outlook
14.6.1. Total Market size of Tuberous Sclerosis Complex
14.6.2. Tuberous Sclerosis Complex Market by Therapies
15. MARKET DRIVERS
16. MARKET BARRIERS
17. APPENDIX
17.1. Report Methodology
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
2. TUBEROUS SCLEROSIS COMPLEX (TSC) MARKET OVERVIEW AT A GLANCE
2.1. Market Share (%) Distribution of TSC in 2017
2.2. Market Share (%) Distribution of TSC in 2027
3. DISEASE OVERVIEW: TUBEROUS SCLEROSIS COMPLEX (TSC)
3.1. Introduction
3.2. Clinical Manifestations of Tuberous Sclerosis Complex
3.3. Etiology
3.4. Risk Factors
3.5. Inheritance Pattern
3.6. Signs and Symptoms
3.7. Pathophysiology
3.7.1. Tuberous Sclerosis Complex (TSC) Genotype Analysis
3.8. Diagnosis
3.8.1. Differential Diagnosis
3.8.2. Diagnostic Criteria
3.8.3. Diagnostic Recommendations
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Population and Forecast Parameters
5. 7MM TOTAL PREVALENT PATIENT POPULATION OF TUBEROUS SCLEROSIS COMPLEX
6. COUNTRY WISE-EPIDEMIOLOGY OF TUBEROUS SCLEROSIS COMPLEX
6.1. United States
6.1.1. Prevalent Population of Tuberous Sclerosis Complex in the United States
6.1.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.1.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.2. Germany
6.2.1. Prevalent Population of Tuberous Sclerosis Complex in Germany
6.2.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.2.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.3. France
6.3.1. Prevalent Population of Tuberous Sclerosis Complex in France
6.3.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.3.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.4. Italy
6.4.1. Prevalent Population of Tuberous Sclerosis Complex in Italy
6.4.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.4.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.5. Spain
6.5.1. Prevalent Population of Tuberous Sclerosis Complex in Spain
6.5.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.5.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.6. United Kingdom
6.6.1. Prevalent Population of Tuberous Sclerosis Complex in the UK
6.6.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.6.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
6.7. Japan
6.7.1. Prevalent Population of Tuberous Sclerosis Complex in Japan
6.7.2. Familiar Prevalent Cases of Tuberous Sclerosis Complex
6.7.3. De novo mutations Prevalent Cases of Tuberous Sclerosis Complex
7. CURRENT TREATMENT PRACTICES
7.1. Therapeutic Goals
7.2. General Treatment Practices
7.3. Treatment Algorithm
7.4. Treatment Guidelines
7.4.1. International Tuberous Sclerosis Complex Consensus Conference: Tuberous Sclerosis Complex Surveillance and Management: Recommendations
8. UNMET NEEDS
9. MARKETED DRUGS
9.1. Comparison of Marketed Drugs
9.2. Everolimus: Novartis Pharmaceuticals
9.2.1. Product Description
9.2.2. Mechanism of Action
9.2.3. Regulatory Milestones
9.2.4. Safety and Efficacy
9.2.5. Side effects
9.2.6. Product Profile
9.3. Rapalimus: Nobelpharma Co., Ltd
9.3.1. Product Description
9.3.2. Mechanism of Action
9.3.3. Regulatory Milestones
9.3.4. Safety and Efficacy
9.3.5. Side effects
9.3.6. Product Profile
10. EMERGING THERAPIES
10.1. Emerging Therapies: Key Cross Comparison
10.2. Epidiolex: GW Pharmaceuticals
10.2.1. Drug Description
10.2.2. Regulatory Milestones
10.2.3. Other Development Activities
10.2.4. Clinical Development
10.2.5. Clinical Trials Information
10.2.6. Product Profile
10.3. TAK-935: Takeda Pharmaceutical Company Limited
10.3.1. Drug Description
10.3.2. Other Development Activities
10.3.3. Clinical Development
10.3.4. Clinical Trials Information
10.3.5. Product Profile
11. TUBEROUS SCLEROSIS COMPLEX: 7 MAJOR MARKET ANALYSIS
11.1. Key Findings
11.2. Market Size of Tuberous Sclerosis Complex in 7MM
12. MARKET OUTLOOK BY COUNTRY
13. THE UNITED STATES: MARKET OUTLOOK
13.1. United States Market Size
13.1.1. Total Market size of Tuberous Sclerosis Complex
13.1.2. Tuberous Sclerosis Complex Market by Therapies
14. EU-5 COUNTRIES: MARKET OUTLOOK
14.1. Germany
14.1.1. Total Market size of Tuberous Sclerosis Complex
14.1.2. Tuberous Sclerosis Complex Market by Therapies
14.2. France
14.2.1. Total Market size of Tuberous Sclerosis Complex
14.2.2. Tuberous Sclerosis Complex Market by Therapies
14.3. United Kingdom
14.3.1. Total Market size of Tuberous Sclerosis Complex
14.3.2. Tuberous Sclerosis Complex Market by Therapies
14.4. Spain
14.4.1. Total Market size of Tuberous Sclerosis Complex
14.4.2. Tuberous Sclerosis Complex Market by Therapies
14.5. Italy
14.5.1. Total Market size of Tuberous Sclerosis Complex
14.5.2. Tuberous Sclerosis Complex Market by Therapies
14.6. Japan: Market Outlook
14.6.1. Total Market size of Tuberous Sclerosis Complex
14.6.2. Tuberous Sclerosis Complex Market by Therapies
15. MARKET DRIVERS
16. MARKET BARRIERS
17. APPENDIX
17.1. Report Methodology
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Characteristics of TSC1 and TSC2 genes
Table 2: Genotype Analysis of TSC1 and TSC2 genes
Table 3: Mutational Analysis of TSC1 and TSC2 genes
Table 4: Molecular Genetic Testing Used in Tuberous Sclerosis Complex
Table 5: Surveillance Recommendations for Diagnosis of Tuberous Sclerosis Complex
Table 6: Tuberous Sclerosis Association Recommendations for Diagnosis of Tuberous Sclerosis Complex
Table 7: Prevalent Patient Population of Tuberous Sclerosis Complex in the 7MM (2016-2027)
Table 8: Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Table 9: Familiar Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Table 10: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Table 11: Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Table 12: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Table 13: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Table 14: Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Table 15: Familiar Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Table 16: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Table 17: Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Table 18: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Table 19: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Table 20: Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Table 21: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Table 22: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Table 23: Prevalent Cases of Tuberous Sclerosis Complex in UK (2016-2027)
Table 24: Familiar Prevalent Cases of Tuberous Sclerosis Complex in UK (2016-2027)
Table 25: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in UK (2016-2027)
Table 26: Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Table 27: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Table 28: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Table 29: Recommendation Categories and Descriptions
Table 30: Class Definitions for Supporting Evidence
Table 31: Surveillance and management recommendations for newly diagnosed or suspected Tuberous Sclerosis Complex (TSC)
Table 32: Surveillance and management recommendations for patients already diagnosed with definite or possible tuberous sclerosis complex (TSC)
Table 33: Epidiolex ,Clinical Trial Description, 2018
Table 34: TAK-935,Clinical Trial Description, 2018
Table 35: 7 Major Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 36: United States Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 37: United States Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 38: Germany Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 39: Germany Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 40: France Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 41: France Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 42: United Kingdom Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 43: United Kingdom Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 44: Spain Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 45: Spain Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 46: Italy Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 47: Italy Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 48: Japan Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 49: Japan Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 1: Characteristics of TSC1 and TSC2 genes
Table 2: Genotype Analysis of TSC1 and TSC2 genes
Table 3: Mutational Analysis of TSC1 and TSC2 genes
Table 4: Molecular Genetic Testing Used in Tuberous Sclerosis Complex
Table 5: Surveillance Recommendations for Diagnosis of Tuberous Sclerosis Complex
Table 6: Tuberous Sclerosis Association Recommendations for Diagnosis of Tuberous Sclerosis Complex
Table 7: Prevalent Patient Population of Tuberous Sclerosis Complex in the 7MM (2016-2027)
Table 8: Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Table 9: Familiar Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Table 10: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Table 11: Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Table 12: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Table 13: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Table 14: Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Table 15: Familiar Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Table 16: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Table 17: Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Table 18: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Table 19: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Table 20: Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Table 21: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Table 22: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Table 23: Prevalent Cases of Tuberous Sclerosis Complex in UK (2016-2027)
Table 24: Familiar Prevalent Cases of Tuberous Sclerosis Complex in UK (2016-2027)
Table 25: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in UK (2016-2027)
Table 26: Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Table 27: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Table 28: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Table 29: Recommendation Categories and Descriptions
Table 30: Class Definitions for Supporting Evidence
Table 31: Surveillance and management recommendations for newly diagnosed or suspected Tuberous Sclerosis Complex (TSC)
Table 32: Surveillance and management recommendations for patients already diagnosed with definite or possible tuberous sclerosis complex (TSC)
Table 33: Epidiolex ,Clinical Trial Description, 2018
Table 34: TAK-935,Clinical Trial Description, 2018
Table 35: 7 Major Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 36: United States Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 37: United States Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 38: Germany Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 39: Germany Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 40: France Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 41: France Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 42: United Kingdom Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 43: United Kingdom Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 44: Spain Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 45: Spain Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 46: Italy Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 47: Italy Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Table 48: Japan Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Table 49: Japan Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
LIST OF FIGURES
Figure 1: Clinical Manifestations of Tuberous Sclerosis Complex
Figure 2: Risk Factors for Tuberous Sclerosis Complex
Figure 3: Inheritance Pattern of Tuberous Sclerosis Complex
Figure 4: Signs and Symptoms of Tuberous Sclerosis Complex
Figure 5: Pathophysiology of Tuberous Sclerosis Complex
Figure 6: Prevalent Patient Population of Tuberous Sclerosis Complex in the 7MM (2016-2027)
Figure 7: Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Figure 8: Familiar Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Figure 9: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Figure 10: Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Figure 11: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Figure 12: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Figure 13: Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Figure 14: Familiar Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Figure 15: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Figure 16: Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Figure 17: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Figure 18: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Figure 19: Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Figure 20: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Figure 21: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Figure 22: Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Figure 23: Familiar Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Figure 24: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Figure 25: Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Figure 26: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Figure 27: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Figure 28: General Treatment Practices of Tuberous Sclerosis Complex
Figure 29: Treatment Algorithm of Tuberous Sclerosis Complex
Figure 30: Unmet Needs of Tuberous Sclerosis Complex
Figure 31: Comparison of Marketed Drugs
Figure 32: Comparison of Emerging Therapies
Figure 33: 7 Major Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Figure 34: Market Size of Tuberous Sclerosis Complex in the United States, USD Millions (2016-2027)
Figure 35: United States Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 36: Market Size of Tuberous Sclerosis Complex in Germany, USD Millions (2016-2027)
Figure 37: Germany Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 38: Market Size of Tuberous Sclerosis Complex in France USD Millions (2016-2027)
Figure 39: France Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 40: Market Size of Tuberous Sclerosis Complex in the United Kingdom, USD Millions (2016-2027)
Figure 41: United Kingdom Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 42: Market Size of Tuberous Sclerosis Complex in Spain, USD Millions (2016-2027)
Figure 43: Spain Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 44: Market Size of Tuberous Sclerosis Complex in Italy, USD Millions (2016-2027)
Figure 45: Italy Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 46: Market Size of Tuberous Sclerosis Complex in the Japan, USD Millions (2016-2027)
Figure 47: Japan Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 48: Market Drivers
Figure 49:Market Barriers
Figure 1: Clinical Manifestations of Tuberous Sclerosis Complex
Figure 2: Risk Factors for Tuberous Sclerosis Complex
Figure 3: Inheritance Pattern of Tuberous Sclerosis Complex
Figure 4: Signs and Symptoms of Tuberous Sclerosis Complex
Figure 5: Pathophysiology of Tuberous Sclerosis Complex
Figure 6: Prevalent Patient Population of Tuberous Sclerosis Complex in the 7MM (2016-2027)
Figure 7: Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Figure 8: Familiar Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Figure 9: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in the United States (2016-2027)
Figure 10: Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Figure 11: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Figure 12: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Germany (2016-2027)
Figure 13: Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Figure 14: Familiar Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Figure 15: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in France (2016-2027)
Figure 16: Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Figure 17: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Figure 18: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Italy (2016-2027)
Figure 19: Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Figure 20: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Figure 21: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Spain (2016-2027)
Figure 22: Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Figure 23: Familiar Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Figure 24: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in the UK (2016-2027)
Figure 25: Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Figure 26: Familiar Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Figure 27: De novo mutations Prevalent Cases of Tuberous Sclerosis Complex in Japan (2016-2027)
Figure 28: General Treatment Practices of Tuberous Sclerosis Complex
Figure 29: Treatment Algorithm of Tuberous Sclerosis Complex
Figure 30: Unmet Needs of Tuberous Sclerosis Complex
Figure 31: Comparison of Marketed Drugs
Figure 32: Comparison of Emerging Therapies
Figure 33: 7 Major Market Size of Tuberous Sclerosis Complex in USD Million (2016-2027)
Figure 34: Market Size of Tuberous Sclerosis Complex in the United States, USD Millions (2016-2027)
Figure 35: United States Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 36: Market Size of Tuberous Sclerosis Complex in Germany, USD Millions (2016-2027)
Figure 37: Germany Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 38: Market Size of Tuberous Sclerosis Complex in France USD Millions (2016-2027)
Figure 39: France Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 40: Market Size of Tuberous Sclerosis Complex in the United Kingdom, USD Millions (2016-2027)
Figure 41: United Kingdom Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 42: Market Size of Tuberous Sclerosis Complex in Spain, USD Millions (2016-2027)
Figure 43: Spain Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 44: Market Size of Tuberous Sclerosis Complex in Italy, USD Millions (2016-2027)
Figure 45: Italy Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 46: Market Size of Tuberous Sclerosis Complex in the Japan, USD Millions (2016-2027)
Figure 47: Japan Tuberous Sclerosis Complex Market by Therapies in USD Million (2016-2027)
Figure 48: Market Drivers
Figure 49:Market Barriers
